Compositions and methods for immunotherapy

a technology of immunotherapy and compositions, applied in the field of compositions and methods for immunotherapy, can solve the problems of significant limitations of dc immunotherapy, as many immunotherapies do, and achieve the effect of improving the immunotherapy

Inactive Publication Date: 2016-05-12
NEXIMMUNE INC
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, DC immunotherapy, like many i...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for immunotherapy
  • Compositions and methods for immunotherapy
  • Compositions and methods for immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Design of Germline Humanized Variable Regions and Human Constant Region Sequences

[0101]This Example demonstrates, inter alia, a design of sequences for germline humanized (CDR grafted) antibodies from a mouse anti-CD28 antibody template; a design of human constant region sequences including human IgG4 containing the S241P (Kabat numbering) hinge stabilizing mutation, the L248E (Kabat numbering) mutation to remove residual Fc gamma receptor binding and a Cys residue (S473C, Kabat numbering) suitable for coupling the antibody; a design of a variant germline humanized antibody V domain with potential non-binding to CD28; a design of a linker sequence for the fusion of HLA-A*02:01 to the N-terminus of the germline humanized antibodies that does not contain potential T cell epitopes.

[0102]The starting anti-CD28 antibody was the murine 9.3 monoclonal antibody (Tan et al. J. Exp. Med. 1993 177:165). Structural models of the 9.3 antibody V regions were produced using Swiss PDB and analyzed ...

example 2

Design of Linkers for Fusion of HLA-A*02:01 to Humanized Antibodies

[0112]Linkers for the fusion of HLA-A*02:01 (IMGT Accession No. HLA00005) to the N-terminus of humanized anti-CD28 antibodies were constructed and incorporated analysis by iTope™ and TCED™ to remove potential immunogenicity.

[0113]The iTope™ software predicts favorable interactions between amino acid side chains of a peptide and specific binding pockets (in particular pocket positions; p1, p4, p6, p7 and p9) within the open-ended binding grooves of 34 human MHC class II alleles. These alleles represent the most common HLA-DR alleles found world-wide with no weighting attributed to those found most prevalently in any particular ethnic population. Twenty of the alleles contain the ‘open’ p1 configuration and fourteen contain the ‘closed’ configuration where glycine at position 83 is replaced by a valine. The location of key binding residues is achieved by the in silico generation of 9 mer peptides that overlap by one am...

example 3

Codon Optimization of Sequences and Expression Cloning

[0119]Codons were optimized using GeneOptimizer®, and optimized sequences were cloned for expression as shown below.

[0120]Sequences were engineered with PmeI restriction sites, Kozak sequence, and signal peptide for expression in NS0 cells. Translation starts immediately downstream of the Kozak sequence.

[0121]The full translated amino acid sequence of the HLA-IgG4HC fusion is shown in FIG. 10.

[0122]The translated sequence of LC3 (VK3) is shown in FIG. 11.

[0123]The translated sequence for HC1 is shown in FIG. 12.

[0124]The translated sequence for HC2 is shown in FIG. 13.

[0125]Human β2 microglobulin was also expressed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

Description

PRIORITY[0001]This Application claims the benefit of and priority to, U.S. Provisional Application No. 61 / 838,547, filed Jun. 24, 2013, and U.S. Provisional Application No. 61 / 948,916, filed Mar. 6, 2014, which are hereby incorporated by reference in their entireties.FIELD OF THE INVENTION[0002]The present invention relates to compositions, including pharmaceutical compositions, and methods that are useful for immunotherapy.BACKGROUND[0003]An antigen-presenting cell (APC) is a cell that processes and displays antigenic peptides in complexes with major histocompatibility complex (MHC) proteins on their surfaces. Effector cells, such as T-cells, may recognize these peptide-MHC (pMHC) complexes using receptors, such as T-cell receptors (TCRs).[0004]Dendritic cells (DCs) are an example of an antigen presenting cell that can be stimulated to effectively present antigen and support expansion of immune effect cells, thereby activating a cytotoxic response towards an antigen. In some immuno...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/48A61K38/17A61K39/00C12N9/02C07K16/46C07K14/74A61K39/44A61K39/395C07K16/28
CPCA61K47/48915C12Y114/18001A61K38/1774A61K39/0011C07K16/2818C07K16/465C07K14/70539A61K39/44C12N9/0071A61K2039/6093C07K2317/565C07K2317/20C07K2317/52C07K2319/30C07K2317/94C07K2317/75C07K2317/24A61K2039/505A61K2039/605A61K39/3955A61K39/39A61K47/6937A61P35/00A61P37/02A61K2039/55555A61K39/001156A61K39/001184A61K39/001186A61K39/001188A61K39/001191A61K39/001192A61K47/60A61K39/395
Inventor MCCREEDY, BRUCEJONES, TIMOTHY DAVIDCARR, FRANCIS JOSEPH
Owner NEXIMMUNE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap